Search the Newsreel

Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed its "Buy" rating for Voyager Therapeutics (NASDAQ:VYGR), contributing to a "Moderate Buy" consensus and a $16.50 price target from analysts. The company reported adjusted quarterly losses of $0.40 per share, surpassing estimates, but revenue of $3.17 million fell short of expectations. …

The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Voyager Therapeutics (NASDAQ:VYGR) recently released its second-quarter results, leading to a 7.9% increase in share price. While revenues were lower than analyst predictions, losses per share were also smaller than expected. Analysts have updated their forecasts, increasing revenue estimates for 2026 but also raising …

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Voyager Therapeutics recently released its second-quarter results, and analysts have updated their forecasts for the company's performance this year and beyond. The consensus earnings per share estimates for 2026 have been significantly reduced, although revenue projections remain largely stable. Despite a challenging outlook, analysts …

Voyager Therapeutics (VYGR) Stock Rebounds While Cash Runway Concerns Persist

Voyager Therapeutics (VYGR) stock saw a 4.5% rebound despite reporting another quarterly loss, with basic EPS at US$0.40 in the red. The company's revenue declined to US$3.17 million from US$5.20 million in the prior year, though net losses narrowed. While clinical milestones like FDA …

Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8

Wedbush has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained a target price of $8. This indicates continued confidence in the company's performance and future prospects from the investment firm.

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) reported a Q2 loss of $0.4 per share, surpassing the Zacks Consensus Estimate of a $0.55 loss. However, the company missed revenue estimates, posting $3.17 million against an expectation of $3.49 million. Despite outperforming EPS estimates in the last four quarters, …

VOYAGER THERAPEUTICS Q2 COLLABORATION REVENUE USD 3.165 MILLION

Voyager Therapeutics reported collaboration revenue of $3.165 million for the second quarter. This financial update provides key insight into the company's performance during this period, specifically highlighting revenue generated through its collaborative efforts.

Is Voyager Therapeutics Inc (VYGR) Overvalued After Q2 Earnings

Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results

VYGR Looks 86.3% Overvalued on GF Value™

Voyager Therapeutics Inc (NASDAQ: VYGR) missed revenue expectations in Q2 2026, reporting $3.17 million against an anticipated $4.56 million, and is focusing on tau-targeted Alzheimer's therapies. Despite its current stock price of $3.13, its GF Value™ suggests it is 86.3% overvalued at $1.68, reflecting …

Voyager Therapeutics reports Q2 2026 net loss $24.5M, cash $148.8M; runway into 2028

Voyager Therapeutics reported a Q2 2026 net loss of $24.5 million on collaboration revenue of $3.2 million, ending the period with $148.8 million in cash, cash equivalents, and marketable securities. The company anticipates this liquidity, combined with expected collaboration reimbursements and interest, will fund …

Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates

Voyager Therapeutics Inc (NASDAQ: VYGR) reported a second-quarter EPS of $-0.400, surpassing analyst estimates by $0.10. However, the company's revenue of $3.17M fell short of the consensus estimate of $4.74M. The stock has seen a decline of -22.720% in the last three months and …

Voyager Therapeutics: Q2 Earnings Snapshot

Voyager Therapeutics Inc. (VYGR) reported a Q2 loss of $24.5 million, or 40 cents per share, which exceeded Wall Street expectations for a loss of 55 cents per share. However, the gene therapy company's revenue of $3.2 million fell short of the $3.5 million …

Voyager Reports Second Quarter 2026 Financial and Operating Results

Voyager Therapeutics, Inc. reported its second quarter 2026 financial and operating results, highlighting progress in its Alzheimer's disease programs, VY7523 and VY1706, with clinical data and trial initiation expected in Q4 2026. The company ended the quarter with $149 million in cash, providing a …

Voyager Therapeutics (Nasdaq: VYGR) gains FDA IND clearance for VY1706

Voyager Therapeutics, Inc. Share Price Live Today – NASDAQ:VYGR Stock Price, Chart, News, History

Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Voyager Therapeutics Inc is projected to report a loss of 48 cents per share in its upcoming earnings. This information is provided as an earnings preview from Refinitiv via Reuters. The full article content is accessible on TradingView.

Voyager Therapeutics (VYGR): Millennium entities disclose 7.4% beneficial stake in Schedule 13G/A

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have disclosed a beneficial ownership of 7.4% in Voyager Therapeutics (VYGR) common stock through a Schedule 13G/A filing. Integrated Core Strategies (US) LLC also reported a 7.3% stake. The filing clarifies that while …

Voyager Therapeutics Inc (VYGR) Institutional Confidence

Voyager Therapeutics Inc (VYGR) has an institutional shareholding score of 5.00, ranking 132nd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 65.36%, marking an 18.22% quarter-over-quarter increase. Key institutional shareholders include Neurocrine Biosciences Inc, EcoR1 Capital, LLC, and Armistice …

Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Voyager Therapeutics Inc (VYGR), outlining major shareholders and institutional holdings. It provides a breakdown of proportional ownership by various entity types and tracks changes in institutional shareholding and individual shareholder activity over recent quarters. The data indicates …

Voyager Therapeutics Inc (VYGR) Cash Flow

This article provides a detailed cash flow statement for Voyager Therapeutics Inc (VYGR), covering quarterly and annual data for operating, investing, and financing activities. It presents historical financial figures and year-over-year changes for various cash flow components. Additionally, the article includes an FAQ section …

TradingKey

This article provides a detailed quarterly and annual income statement for Voyager Therapeutics Inc. (VYGR), covering financial performance metrics such as total revenue, operating expenses, net income, and earnings per share from FY2014Q1 to FY2026Q1. It also includes FAQs explaining how to interpret the …

Voyager Therapeutics Inc (VYGR) Financial Health: Profitability & Balance Sheet Analysis

Voyager Therapeutics Inc (VYGR) has a current financial score of 5.98, placing it 303rd out of 386 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue was $2.59 million, a 59.94% year-over-year decrease, …

Voyager Therapeutics, Inc. Revenue Breakdown – NASDAQ:VYGR

Voyager Therapeutics, Inc. (NASDAQ: VYGR) generated $40.37 million in revenue last year, with its Genetic Medicine segment being the sole contributor. This marked a decrease from $80.00 million reported in the previous year. The United States was the primary source of revenue for the …

H.C. Wainwright reiterates Voyager Therapeutics stock rating on tau therapy data

H.C. Wainwright has reiterated a Buy rating and a $25.00 price target for Voyager Therapeutics (NASDAQ:VYGR) following positive updated preclinical data from its tau-silencing gene therapy program, VY1706. The data showed sustained tau reduction in non-human primates and supported the FDA's clearance of an …

Voyager Therapeutics Q1 2026 Earnings: EPS Beat Narrowly Misses Revenue Visibility as Stock Slips

VYGR Forecast — Price Target — Prediction for 2027

Voyager Therapeutics (VYGR) Q1 2026 Earnings: EPS Beat of 16.4% Amid Continued Pipeline Progress - Guidance vs Actual

Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates

Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky

Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results?

Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?